Business Description
iSpecimen Inc
NAICS : 621512
SIC : 8734
ISIN : US45032V2079
Total Employee Number:
7Description
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.06 | |||||
Equity-to-Asset | 0.12 | |||||
Debt-to-Equity | 0.31 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -23.4 | |||||
Beneish M-Score | -7.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -73.9 | |||||
3-Year EBITDA Growth Rate | 54.4 | |||||
3-Year EPS without NRI Growth Rate | 53.9 | |||||
3-Year FCF Growth Rate | 61.8 | |||||
3-Year Book Growth Rate | -80.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 105.21 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 22.39 | |||||
9-Day RSI | 29.34 | |||||
14-Day RSI | 32.27 | |||||
3-1 Month Momentum % | -48.62 | |||||
6-1 Month Momentum % | -82.54 | |||||
12-1 Month Momentum % | -93.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.62 | |||||
Quick Ratio | 0.62 | |||||
Cash Ratio | 0.5 | |||||
Days Inventory | 12.33 | |||||
Days Sales Outstanding | 89.19 | |||||
Days Payable | 1257.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -168.1 | |||||
Shareholder Yield % | 6.49 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -29.57 | |||||
Operating Margin % | -960.8 | |||||
Net Margin % | -1080.16 | |||||
EBITDA Margin % | -940.47 | |||||
FCF Margin % | -701.07 | |||||
OCF Margin % | -632.98 | |||||
ROE % | -599.18 | |||||
ROA % | -146.04 | |||||
ROIC % | -219.32 | |||||
3-Year ROIIC % | -48.44 | |||||
ROC (Joel Greenblatt) % | -3368.33 | |||||
ROCE % | -533.96 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.07 | |||||
PB Ratio | 1.8 | |||||
EV-to-EBIT | -0.02 | |||||
EV-to-EBITDA | -0.03 | |||||
EV-to-Revenue | 0.26 | |||||
EV-to-FCF | -0.04 | |||||
Price-to-GF-Value | 0.3 | |||||
Earnings Yield (Greenblatt) % | -5000 | |||||
FCF Yield % | -254.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ISPC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
iSpecimen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.028 | ||
| EPS (TTM) ($) | -325.995 | ||
| Beta | 2.1457 | ||
| 3-Year Sharpe Ratio | -1.43 | ||
| 3-Year Sortino Ratio | -1.65 | ||
| Volatility % | 138.73 | ||
| 14-Day RSI | 32.27 | ||
| 14-Day ATR ($) | 0.2234 | ||
| 20-Day SMA ($) | 2.404 | ||
| 12-1 Month Momentum % | -93.91 | ||
| 52-Week Range ($) | 1.93 - 127.2 | ||
| Shares Outstanding (Mil) | 1.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
iSpecimen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
iSpecimen Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-17 | In 113 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 18 days | ||
| General meeting for 2025 | 2026-05-29 09:00 | 3.32 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-18 | 4.15 (+4.27%) | ||
| 0.025:1 Stock Split | 2026-04-28 | 4.92 (-5.31%) | ||
| Annual report for 2025 | 2026-04-01 | 6.28 (+6.80%) | ||
| Third quarter earnings results for 2025 | 2025-11-17 | 25.10 (+7.82%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 46.40 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-19 | 45.20 (-3.42%) | ||
| Annual report for 2024 | 2025-04-14 | 48.80 (-7.58%) |
Show
Entries
iSpecimen Inc Frequently Asked Questions
What is iSpecimen Inc(ISPC)'s stock price today?
The current price of ISPC is $1.97. The 52 week high of ISPC is $127.20 and 52 week low is $1.93.
When is next earnings date of iSpecimen Inc(ISPC)?
The next earnings date of iSpecimen Inc(ISPC) is 2026-08-14 Est..
Does iSpecimen Inc(ISPC) pay dividends? If so, how much?
iSpecimen Inc(ISPC) does not pay dividend.
Guru Commentaries on NAS:ISPC
No articles.
Press Release
Articles on iSpecimen Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers